Document Type

Article

Publication Date

7-23-2021

Publication Title

Front Aging Neurosci

Keywords

JMG, JGM

JAX Location

Front Aging Neurosci 2021 Jul 23; 13:713726

Volume

13

First Page

713726

Last Page

713726

ISSN

1663-4365

PMID

34366832

DOI

https://doi.org/10.3389/fnagi.2021.713726

Grant

AG054345

Abstract

The ability to investigate therapeutic interventions in animal models of neurodegenerative diseases depends on extensive characterization of the model(s) being used. There are numerous models that have been generated to study Alzheimer's disease (AD) and the underlying pathogenesis of the disease. While transgenic models have been instrumental in understanding AD mechanisms and risk factors, they are limited in the degree of characteristics displayed in comparison with AD in humans, and the full spectrum of AD effects has yet to be recapitulated in a single mouse model. The Model Organism Development and Evaluation for Late-Onset Alzheimer's Disease (MODEL-AD) consortium was assembled by the National Institute on Aging (NIA) to develop more robust animal models of AD with increased relevance to human disease, standardize the characterization of AD mouse models, improve preclinical testing in animals, and establish clinically relevant AD biomarkers, among other aims toward enhancing the translational value of AD models in clinical drug design and treatment development. Here we have conducted a detailed characterization of the 5XFAD mouse, including transcriptomics, electroencephalogram,

Comments

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

Download

Share

COinS